Takeda Gains Approval For HYQVIA In Japan To Treat Immunodeficiency
Takeda Gains Approval For HYQVIA In Japan To Treat Immunodeficiency
武田获批在日本使用HYQVIA治疗免疫缺陷
- HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and Hypogammaglobulinemia
- Administration of Recombinant Human Hyaluronidase Prior to Immunoglobulin Facilitates Subcutaneous Infusion of Larger Volumes, Potentially Reducing Frequency and Giving Patients More Flexibility
- Approval Expands Takeda's Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company's Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan
- HYQVIA [免疫球蛋白注射液 10%（人用）与重组人透明质酸酶] 是日本首个也是唯一一个获批准用于无丙种球蛋白血症和低丙种球蛋白血症的经辅导皮下免疫球蛋白（fSCIG）。
- 在免疫球蛋白之前使用重组人透明质酸酶，可以促进大剂量的皮下注射，可能减少注射频率，并为患者提供更多灵活性。
- 批准扩展了武田药品的差异化免疫球蛋白疗法组合，反映了公司致力于为日本患者提供高质量血浆衍生疗法的承诺。
资讯热榜
更新时间